This trial is evaluating whether Selinexor will improve 2 primary outcomes and 2 secondary outcomes in patients with Metastatic Ureter Urothelial Carcinoma. Measurement will happen over the course of Up to 2 cycles (each cycle is 21 days).
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. Selinexor is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"In contrast to the results of the review, we observed the occurrence of disease recurrence and death after treatment of carcinoma. The prognosis is strongly influenced by patients' age and sex." - Anonymous Online Contributor
"While conventional cancer therapies may have caused severe side effects and low satisfaction rating for patients, many recently developed treatments are expected to improve treatment survival rates and minimize side effects. To further our understanding of the development of novel drugs and therapies for the future, it will be of utmost need to search for prospective treatments in the next generation of medicines." - Anonymous Online Contributor
"If cancers are screened through the general population, and carcinoma is detected at a relatively early stage, there will be significant progress in eliminating the disparity." - Anonymous Online Contributor
"Carcinoma is malignant neoplasm. The malignant neoplasms can be subdivided according to cancer location and type, but the most obvious distinction is between benign and malignant neoplasms." - Anonymous Online Contributor
"In the UK the signs of carcinoma are similar to those of other cancers, such as stomach cancer, kidney cancer, skin cancer or colorectal cancer. All of these forms of cancer may show many similar signs and symptoms. The only exception is lung cancer. In this cancer, symptoms are often non-specific, such as vague malaise and shortness of breath. Patients should often seek their doctor for a medical examination to assess their health properly, especially after a long latency period where some symptoms have been overlooked or misdiagnosed." - Anonymous Online Contributor
"There is little evidence that chemical, genetic, infectious or environmental factors were causal for the development of sporadic cancers. Other factors such as genetic, environmental and lifestyle effects were more likely to play key roles in the causation of certain tumours. Thus, the primary focus of carcinogenesis research should be on these factors." - Anonymous Online Contributor
"A wide range of treatments for carcinoma are used. Most patients prefer active active control of the disease with new antiproliferative agents. Localised radiation is often used on a temporary basis and often is applied in conjunction with antiproliferative drugs. More aggressive and enduring agents including targeted agents are now being explored more broadly. Overall, for carcinoma, we may look to a new generation of drugs." - Anonymous Online Contributor
"A handful of treatment-related adverse events were recorded including fatigue, nausea, abdominal pain, and headache. Most of these events were transient and did not result in discontinuation of selinexor treatment. At the dose of 10 mg in an intermittent schedule, selinexor does not usually cause adverse events but does result in low drug levels." - Anonymous Online Contributor
"The most important prognostic factor for survival for patients with carcinoma of the lung was the depth of invasion. Advanced carcinomas that are invasive into the thoracic wall will have a worse outcome than those that have invaded only to or through the pulmonary fascia. Although survival differences were seen, none could be attributed to the depth of invasion." - Anonymous Online Contributor
"Findings from a recent study failed to demonstrate a clinically meaningful statistically significant improvement in quality of life in the selinexor arm compared with placebo, despite a more objective estimation of QOL in some QOL domains." - Anonymous Online Contributor
"Patients have good expectations and willingness to pay for treatment and follow-up of carcinoma after surgery, but some believe they need no treatment at all." - Anonymous Online Contributor
"There is no absolute age that everyone dies of carcinoma, and we might expect a small number of younger people dying of carcinoma than older persons." - Anonymous Online Contributor